Aptar Reports Second Quarter 2021 Results

Aptar Reports Second Quarter 2021 Results




Aptar Reports Second Quarter 2021 Results

CRYSTAL LAKE, Ill.–(BUSINESS WIRE)–AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions, today reported second quarter results for 2021.


Second Quarter 2021 Summary

  • Reported sales grew 16% driven by strong core sales growth and positive currency effects
  • Core sales (excluding currency effects) increased 10% mainly on double digit core growth in Beauty + Home and Food + Beverage, driven by increased demand for our innovative dispensing solutions along with price adjustments related to rising input costs
  • Reported earnings per share totaled $0.81 (an increase of 29% compared to the prior year)
  • Adjusted earnings per share, excluding restructuring charges, acquisition costs and the loss on an equity investment, totaled $0.91 (an increase of 7% compared to the prior year when neutralizing currency effects)
  • Reported net income totaled $55 million for the second quarter (an increase of 32% compared to the prior year) and $139 million year-to-date (an increase of 43% compared to the prior year)
  • Adjusted EBITDA totaled $148 million for the second quarter (an increase of 8% compared to the prior year) and $300 million year-to-date (an increase of 7% compared to the prior year)
  • Cash flow from operations was $176 million in the first half of 2021 (a decrease of 23% compared to the prior year)
  • Free cash flow was $39 million in the first half of 2021 (a decrease of 63% compared to the prior year) primarily due to increased investments for growth (capital expenditures and working capital)
  • Subsequent to the end of the quarter, the Company announced:

    • A share purchase agreement regarding the acquisition of a majority stake in Voluntis, a pioneer in digital therapeutics
    • A strategic collaboration with YAT, a Chinese online skincare company, to develop a range of products and services for the skincare market
    • An agreement to acquire 80% of Weihai Hengyu Medical Products, adding elastomeric and plastic component manufacturing capabilities in China for injectable drug delivery

Second Quarter Results

For the quarter ended June 30, 2021, reported sales increased 16% to $811 million compared to $699 million in the prior year. Core sales, excluding the impact from changes in currency exchange rates, increased 10%.

Second Quarter Segment Sales Analysis

(Change Over Prior Year)

Pharma

Beauty + Home

Food + Beverage

Total AptarGroup

Core Sales Growth

2%

13%

23%

10%

Acquisitions

0%

0%

0%

0%

Currency Effects (1)

6%

7%

5%

6%

Total Reported Sales Growth

8%

20%

28%

16%

(1) – Currency effects are approximated by translating last year’s amounts at this year’s foreign exchange rates.

Commenting on the quarter, Stephan B. Tanda, President and CEO, said, “The wide breadth of our innovative solutions and services, serving thousands of customers across multiple markets, continues to be a strength of Aptar. We achieved core sales growth in each segment and consolidated double-digit core sales growth despite the ongoing reduction of allergic rhinitis and cough and cold product inventory levels by customers served by our prescription drug and consumer healthcare units. We will continue to take action to mitigate the effects of a rising input cost environment, which compressed our margins during the quarter, particularly in Beauty + Home and Food + Beverage. Despite the issues we faced in the quarter, we expect a recovery in the second half, especially as we get toward the end of the year.”

Aptar’s Beauty + Home segment generated strong core sales growth over the prior year second quarter, which was the height of the pandemic. Approximately 75% of the growth came from increased volumes. Increased sales to the beauty market were driven by demand for fragrance and facial skincare solutions. In the personal care market, increased sales to the hair care and sun care market were offset by declines in personal cleansing, as hand sanitizer demand began to normalize. The home care market experienced another solid quarter with strong demand for Aptar’s valves and pumps for a variety of applications. Price adjustments related to the initial passing through of higher resin and other input costs, and increased tooling sales, also contributed to the top line in the quarter.

Aptar’s Food + Beverage segment reported double-digit core sales growth with price adjustments related to higher resin costs accounting for approximately 60% of the sales increase. Volumes rose on increased demand for specialty food dispensing closures as consumers continued to cook at home, along with modest recovery in the beverage market compared to the prior year.

In the Pharma segment, increased demand for elastomeric components used with injected medicines and active material science solutions more than offset declines in the prescription drug and consumer health care markets. Similar to the first quarter, certain areas of the Pharma segment continue to be impacted by customers drawing down inventory levels as sectors such as allergic rhinitis and cough and cold have been impacted by low levels of patient consumption during the pandemic.

Aptar reported second quarter earnings per share of $0.81 compared to $0.63 during the same period a year ago, an increase of 29%. Second quarter adjusted earnings per share, excluding restructuring charges, acquisitions costs and the loss on an equity investment, were $0.91 and increased 7% from the prior year adjusted earnings per share, including comparable exchange rates, of $0.85.

Year-to-Date Results

For the six months ended June 30, 2021, reported sales increased 12% to $1.59 billion compared to $1.42 billion in the prior year. Core sales, excluding the impacts from changes in currency exchange rates and acquisitions, increased 5%.

Six Months Year-to-Date Segment Sales Analysis
(Change Over Prior Year)

Pharma

Beauty + Home

Food + Beverage

Total AptarGroup

Core Sales Growth

1%

5%

18%

5%

Acquisitions

0%

3%

0%

1%

Currency Effects (1)

6%

5%

4%

6%

Total Reported Sales Growth

7%

13%

22%

12%

(1) – Currency effects are approximated by translating last year’s amounts at this year’s foreign exchange rates.

Tanda commented on the year-to-date results, “I’m proud of the dedicated efforts of our people and the resiliency and agility we have shown in the first half of the year. We achieved core sales growth in each segment, and consolidated top line core sales growth of 5% with adjusted EBITDA growth of 7%. This is despite headwinds from the unprecedented inflationary environment even though we are implementing pricing adjustments to pass on these effects over time.”

For the six months year-to-date, Aptar’s reported earnings per share were $2.05, and increased 39%, compared to $1.47 reported a year ago. Current year adjusted earnings per share, excluding restructuring charges, acquisitions costs and the net gain on an equity investment, were $2.01 and increased 10% from prior year adjusted earnings per share, including comparable exchange rates, of $1.83. Free cash flow for the first six months was impacted by higher capital expenditures and changes in working capital, mainly increases in inventory and accounts receivable related to the recent sales growth and order activity.

Outlook

For the third quarter, the broader macro factors impacting our business are not anticipated to change dramatically from what we experienced in the second quarter. Looking ahead, we believe the second half will initially show gradually improving operating results from our position today, and we expect accelerated improvement toward the end of the year,” said Tanda.

Third quarter results are anticipated to reflect continued gradual improvement in Aptar’s beauty and beverage businesses as the reopening of economies is expected to continue at a measured pace given the uncertainties around the COVID-19 variants and limited resumption of intercontinental travel. The current inventory destocking cycle by our customers in the prescription drug market is expected to continue through the third quarter, with improving performance toward the end of the year. Additionally, Aptar expects ongoing steady demand for elastomer components for injection devices in the third quarter. The exceptionally strong custom tooling sales reported in the prior year third quarter by the Pharma segment’s active material science solutions division, is not expected to repeat. While inflation and cost pressures continue to be a headwind, especially in raw material and transportation costs, Aptar will look to implement further price adjustments as necessary to pass on these costs over time.

As we navigate through what has become a rather bumpy growth trajectory across our different markets, we continue to focus on returns across all areas of our business and anticipate that our consolidated margins will improve as we transition to a more balanced and steady growth pattern,” said Tanda. “Our long-term views have not changed. This is a tremendous company with outstanding talent and the fundamental growth story is intact across each of our markets. In addition, we are taking strategic actions such as our recently announced investments in complementary, high-quality businesses that will contribute to that story.”

Aptar expects earnings per share for the third quarter of 2021, excluding any restructuring expenses, acquisition costs and changes in the fair value of equity investments, to be in the range of $0.90 to $0.98 and this guidance is based on an effective tax rate range of 28% to 30%.

Cash Dividend

As previously announced, Aptar’s Board of Directors declared a quarterly cash dividend of $0.38 per share. The payment date is August 25, 2021, to stockholders of record as of August 4, 2021.

Open Conference Call

There will be a conference call on Friday, July 30, 2021 at 8:00 a.m. Central Time to discuss the Company’s second quarter results for 2021. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investor Relations page at www.aptar.com. Replay of the conference call can also be accessed for a limited time on the Investor Relations page of the website.

About Aptar

Aptar is a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions. Aptar’s innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, personal care, home, food and beverage. Using insights, proprietary design, engineering and science to create dispensing, dosing and protective technologies for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com.

Presentation of Non-GAAP Information

This press release refers to certain non-GAAP financial measures, including current year adjusted earnings per share and adjusted EBITDA, which exclude the impact of business transformation charges (restructuring initiatives), acquisition-related costs, certain purchase accounting adjustments related to acquisitions and investments and net investment gains and losses related to observable market price changes on equity securities. Core sales and adjusted earnings per share also neutralize the impact of foreign currency translation effects when comparing current results to the prior year. Non-GAAP financial measures may not be comparable to similarly titled non-GAAP financial measures provided by other companies. Aptar’s management believes these non-GAAP financial measures provide useful information to our investors because they allow for a better period over period comparison of operating results by removing the impact of items that, in management’s view, do not reflect Aptar’s core operating performance. These non-GAAP financial measures also provide investors with certain information used by Aptar’s management when making financial and operational decisions. Free cash flow is calculated as cash provided by operating activities less capital expenditures. We use free cash flow to measure cash flow generated by operations that is available for dividends, share repurchases, acquisitions and debt repayment. We believe that it is meaningful to investors in evaluating our financial performance and measuring our ability to generate cash internally to fund our initiatives. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial results but should be read in conjunction with the unaudited condensed consolidated statements of income and other information presented herein. A reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures is included in the accompanying tables. Our outlook is provided on a non-GAAP basis because certain reconciling items are dependent on future events that either cannot be controlled, such as exchange rates and changes in the fair value of equity investments, or reliably predicted because they are not part of the Company’s routine activities, such as restructuring and acquisition costs.

This press release contains forward-looking statements, including certain statements set forth under the “Outlook” section of this press release. Words such as “expects,” “anticipates,” “believes,” “estimates,” “future,” “potential” and other similar expressions or future or conditional verbs such as “will,” “should,” “would” and “could” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: pandemics, including the impact of the COVID-19 pandemic on our global supply chain and our global customers and operations; our ability to preserve organizational culture and maintain employee productivity in the work-from-home environment caused by the current pandemic; the successful integration of acquisitions and the achievement of the expected benefits of acquisitions and investments; the impact of tax reform legislation including changes in tax rates and other tax-related events or transactions that could impact our effective tax rate; the execution of the business transformation plan; economic conditions worldwide including potential deflationary or inflationary conditions or economic downturn or uncertainty in regions we rely on for growth as a result of the COVID-19 pandemic or otherwise; political conditions worldwide; significant fluctuations in foreign currency exchange rates; changes in customer and/or consumer spending levels; financial conditions of customers and suppliers; consolidations within our customer or supplier bases; the availability of direct labor workers and the increase in direct labor costs; fluctuations in the cost of materials, components and other input costs; the availability of raw materials and components; our ability to successfully implement facility expansions and new facility projects; our ability to increase prices, contain costs and improve productivity; changes in capital availability or cost, including interest rate fluctuations; volatility of global credit markets; cybersecurity threats that could impact our networks and reporting systems; fiscal and monetary policies and other regulations; direct or indirect consequences of acts of war or terrorism; and work stoppages due to labor disputes. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K and Form 10-Qs. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

AptarGroup, Inc.
Condensed Consolidated Financial Statements (Unaudited)
(In Thousands, Except Per Share Data)
Consolidated Statements of Income
 

Three Months Ended

Six Months Ended

June 30,

June 30,

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 
Net Sales

$

811,032

 

$

699,305

 

$

1,587,786

 

$

1,420,858

 

Cost of Sales (exclusive of depreciation and amortization shown below)

 

523,050

 

 

441,702

 

 

1,011,755

 

 

892,958

 

Selling, Research & Development and Administrative

 

140,913

 

 

123,365

 

 

275,261

 

 

249,557

 

Depreciation and Amortization

 

57,790

 

 

56,429

 

 

115,228

 

 

107,235

 

Restructuring Initiatives

 

4,876

 

 

7,331

 

 

8,548

 

 

12,170

 

Operating Income

 

84,403

 

 

70,478

 

 

176,994

 

 

158,938

 

Other Income (Expense):
Interest Expense

 

(7,175

)

 

(8,734

)

 

(14,590

)

 

(17,122

)

Interest Income

 

624

 

 

175

 

 

1,005

 

 

350

 

Net Investment (Loss) Gain

 

(1,611

)

 

 

 

15,198

 

 

 

Equity in Results of Affiliates

 

81

 

 

(328

)

 

(434

)

 

(1,127

)

Miscellaneous, net

 

(2,028

)

 

(923

)

 

(2,991

)

 

(2,335

)

Income before Income Taxes

 

74,294

 

 

60,668

 

 

175,182

 

 

138,704

 

Provision for Income Taxes

 

19,020

 

 

18,808

 

 

35,969

 

 

41,594

 

Net Income

$

55,274

 

$

41,860

 

$

139,213

 

$

97,110

 

Net Loss (Income) Attributable to Noncontrolling Interests

 

2

 

 

(21

)

 

15

 

 

(18

)

Net Income Attributable to AptarGroup, Inc.

$

55,276

 

$

41,839

 

$

139,228

 

$

97,092

 

Net Income Attributable to AptarGroup, Inc. per Common Share:
Basic

$

0.84

 

$

0.65

 

$

2.12

 

$

1.51

 

Diluted

$

0.81

 

$

0.63

 

$

2.05

 

$

1.47

 

 
Average Numbers of Shares Outstanding:
Basic

 

65,818

 

 

64,262

 

 

65,525

 

 

64,135

 

Diluted

 

68,086

 

 

66,384

 

 

67,869

 

 

66,246

 

 
AptarGroup, Inc.
Condensed Consolidated Financial Statements (Unaudited)
(continued)
($ In Thousands)
Consolidated Balance Sheets
 

June 30, 2021

December 31, 2020

ASSETS
 
Cash and Equivalents

$

291,495

$

300,137

Short-term Investments

 

 

243

Total Cash and Equivalents, and Short-term Investments

 

291,495

 

300,380

Accounts and Notes Receivable, Net

 

635,847

 

566,623

Inventories

 

429,440

 

379,379

Prepaid and Other Current Assets

 

135,672

 

122,613

Total Current Assets

 

1,492,454

 

1,368,995

Property, Plant and Equipment, Net

 

1,224,455

 

1,198,748

Goodwill

 

887,741

 

898,521

Other Assets

 

505,452

 

523,789

Total Assets

$

4,110,102

$

3,990,053

 
LIABILITIES AND EQUITY
 
Short-Term Obligations

$

70,208

$

117,866

Accounts Payable, Accrued and Other Liabilities

 

712,358

 

662,463

Total Current Liabilities

 

782,566

 

780,329

Long-Term Obligations

 

1,048,928

 

1,054,998

Deferred Liabilities and Other

 

291,945

 

303,941

Total Liabilities

 

2,123,439

 

2,139,268

 
AptarGroup, Inc. Stockholders’ Equity

 

1,986,282

 

1,850,389

Noncontrolling Interests in Subsidiaries

 

381

 

396

Total Equity

 

1,986,663

 

1,850,785

 
Total Liabilities and Equity

$

4,110,102

$

3,990,053

 
AptarGroup, Inc.
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited)
($ In Thousands)
 

Three Months Ended

June 30, 2021

 

Consolidated

Pharma

Beauty + Home

Food + Beverage

Corporate & Other

Net Interest

Net Sales

$

811,032

 

 

325,343

 

 

360,246

 

 

125,443

 

 

 

 

 

 
Reported net income

$

55,274

 

Reported income taxes

 

19,020

 

Reported income before income taxes

 

74,294

 

 

81,806

 

 

12,122

 

 

9,691

 

 

(22,774

)

 

(6,551

)

Adjustments:
Restructuring initiatives

 

4,876

 

 

38

 

 

1,457

 

 

117

 

 

3,264

 

Net investment loss

 

1,611

 

 

1,611

 

Transaction costs related to acquisitions

 

2,434

 

 

2,434

 

Adjusted earnings before income taxes

 

83,215

 

 

84,278

 

 

13,579

 

 

9,808

 

 

(17,899

)

 

(6,551

)

Interest expense

 

7,175

 

 

7,175

 

Interest income

 

(624

)

 

(624

)

Adjusted earnings before net interest and taxes (Adjusted EBIT)

 

89,766

 

 

84,278

 

 

13,579

 

 

9,808

 

 

(17,899

)

 

 

Depreciation and amortization

 

57,790

 

 

21,701

 

 

24,331

 

 

9,818

 

 

1,940

 

 

 

Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)

$

147,556

 

$

105,979

 

$

37,910

 

$

19,626

 

$

(15,959

)

$

 

 
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)

 

18.2

%

 

32.6

%

 

10.5

%

 

15.6

%

 

Three Months Ended

June 30, 2020

 

Consolidated

Pharma

Beauty + Home

Food + Beverage

Corporate & Other

Net Interest

Net Sales

$

699,305

 

 

301,259

 

 

299,786

 

 

98,260

 

 

 

 

 

 
Reported net income

$

41,860

 

Reported income taxes

 

18,808

 

Reported income before income taxes

 

60,668

 

 

85,467

 

 

(12,755

)

 

8,519

 

 

(12,004

)

 

(8,559

)

Adjustments:
Restructuring initiatives

 

7,331

 

 

(111

)

 

7,324

 

 

75

 

 

43

 

Transaction costs related to acquisitions

 

3,207

 

 

3,207

 

Purchase accounting adjustments related to acquisitions and investments

 

3,252

 

 

293

 

 

2,959

 

Adjusted earnings before income taxes

 

74,458

 

 

85,649

 

 

735

 

 

8,594

 

 

(11,961

)

 

(8,559

)

Interest expense

 

8,734

 

 

8,734

 

Interest income

 

(175

)

 

(175

)

Adjusted earnings before net interest and taxes (Adjusted EBIT)

 

83,017

 

 

85,649

 

 

735

 

 

8,594

 

 

(11,961

)

 

 

Depreciation and amortization

 

56,429

 

 

18,617

 

 

25,939

 

 

9,191

 

 

2,682

 

 

 

Purchase accounting adjustments included in Depreciation and amortization above

 

(2,867

)

 

(167

)

 

(2,700

)

Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)

$

136,579

 

$

104,099

 

$

23,974

 

$

17,785

 

$

(9,279

)

$

 

 
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)

 

19.5

%

 

34.6

%

 

8.0

%

 

18.1

%

 
AptarGroup, Inc.
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited)
($ In Thousands)
 

Six Months Ended

June 30, 2021

 

Consolidated

Pharma

Beauty + Home

Food + Beverage

Corporate & Other

Net Interest

Net Sales

$

1,587,786

 

 

639,175

 

 

707,192

 

 

241,419

 

 

 

 

 

 
Reported net income

$

139,213

 

Reported income taxes

 

35,969

 

Reported income before income taxes

 

175,182

 

 

169,476

 

 

21,810

 

 

19,701

 

 

(22,220

)

 

(13,585

)

Adjustments:
Restructuring initiatives

 

8,548

 

 

73

 

 

2,553

 

 

38

 

 

5,884

 

Net investment gain

 

(15,198

)

 

(15,198

)

Transaction costs related to acquisitions

 

2,434

 

 

2,434

 

Adjusted earnings before income taxes

 

170,966

 

 

171,983

 

 

24,363

 

 

19,739

 

 

(31,534

)

 

(13,585

)

Interest expense

 

14,590

 

 

14,590

 

Interest income

 

(1,005

)

 

(1,005

)

Adjusted earnings before net interest and taxes (Adjusted EBIT)

 

184,551

 

 

171,983

 

 

24,363

 

 

19,739

 

 

(31,534

)

 

 

Depreciation and amortization

 

115,228

 

 

42,480

 

 

48,903

 

 

19,877

 

 

3,968

 

 

 

Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)

$

299,779

 

$

214,463

 

$

73,266

 

$

39,616

 

$

(27,566

)

$

 

 
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)

 

18.9

%

 

33.6

%

 

10.4

%

 

16.4

%

 

Six Months Ended

June 30, 2020

 

Consolidated

Pharma

Beauty + Home

Food + Beverage

Corporate & Other

Net Interest

Net Sales

$

1,420,858

 

 

598,455

 

 

624,346

 

 

198,057

 

 

 

 

 

 
Reported net income

$

97,110

 

Reported income taxes

 

41,594

 

Reported income before income taxes

 

138,704

 

 

175,321

 

 

(5,647

)

 

14,481

 

 

(28,679

)

 

(16,772

)

Adjustments:
Restructuring initiatives

 

12,170

 

 

(142

)

 

12,231

 

 

178

 

 

(97

)

Transaction costs related to acquisitions

 

4,591

 

 

4,591

 

Purchase accounting adjustments related to acquisitions and investments

 

4,642

 

 

1,421

 

 

3,221

 

Adjusted earnings before income taxes

 

160,107

 

 

176,600

 

 

14,396

 

 

14,659

 

 

(28,776

)

 

(16,772

)

Interest expense

 

17,122

 

 

17,122

 

Interest income

 

(350

)

 

(350

)

Adjusted earnings before net interest and taxes (Adjusted EBIT)

 

176,879

 

 

176,600

 

 

14,396

 

 

14,659

 

 

(28,776

)

 

 

Depreciation and amortization

 

107,235

 

 

36,508

 

 

46,525

 

 

18,533

 

 

5,669

 

 

 

Purchase accounting adjustments included in Depreciation and amortization above

 

(3,367

)

 

(667

)

 

(2,700

)

Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)

$

280,747

 

$

212,441

 

$

58,221

 

$

33,192

 

$

(23,107

)

$

 

 
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)

 

19.8

%

 

35.5

%

 

9.3

%

 

16.8

%

 

Contacts

Investor Relations Contact:

Matt DellaMaria

matt.dellamaria@aptar.com
815-479-5530

Media Contact:

Katie Reardon

katie.reardon@aptar.com
815-479-5671

Read full story here